AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27939058 — intervention group
Group type: COMPARATOR
Intervention: Continuation of open fire cooking (Control)
Number of subjects: 10750
Study 25630866 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during flexible cystoscopy
Number of subjects: 137
Study 25630866 — intervention group
Group type: COMPARATOR
Intervention: Nonmusic group (control)
Number of subjects: 137
Study 23760943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 23
Study 23760943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 21454834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass-ceramic (LDGC) restorations
Number of subjects: 0
Study 21454834 — intervention group
Group type: COMPARATOR
Intervention: Zirconium oxide (Y-TZP) restorations
Number of subjects: 0
Study 19167953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99
Study 19167953 — intervention group
Group type: COMPARATOR
Intervention: American Diabetes Association guidelines diet
Number of subjects: 99
Study 19167953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 99
Study 17127227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g t.i.d. of imipenem/cilastatin (group A)
Number of subjects: 20
Study 17127227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g t.i.d. of meropenem (group B)
Number of subjects: 20
Study 17127227 — intervention group
Group type: COMPARATOR
Intervention: Both carbapenems (imipenem and meropenem)
Number of subjects: 20
Study 14985312 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC412 150 mg/d
Number of subjects: 141
Study 14985312 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC412 100 mg/d
Number of subjects: 141
Study 14985312 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC412 100 mg/d and 150 mg/d
Number of subjects: 141
Study 14985312 — intervention group
Group type: COMPARATOR
Intervention: PKC412 50 mg/d, 100 mg/d, 150 mg/d
Number of subjects: 141
Study 11729699 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 0
Study 11729699 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study 9924222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine up to 2 mg kg‐1, infiltrated around the inferior alveolar nerves bilaterally
Number of subjects: 40
Study 9924222 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg i.v. at the start of surgery
Number of subjects: 40
Study 7822072 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with previous severe unilateral ankle sprain
Number of subjects: 0
Study 7822072 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 0
Study 2975610 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 13
Study 2975610 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 13
Study 31779923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 31779923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study 30585472 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture plus motor relearning training
Number of subjects: 80
Study 30585472 — intervention group
Group type: COMPARATOR
Intervention: Motor relearning training
Number of subjects: 80
Study 25130262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g day(-1) omega-3 PUFAs plus cognitive behavioural case management
Number of subjects: 400
Study 25130262 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive behavioural case management
Number of subjects: 400
Study 25073573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5mg
Number of subjects: 0
Study 25073573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10mg
Number of subjects: 0
Study 25073573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25073573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 0
Study 22619101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial relaxation along with conventional therapeutic exercises
Number of subjects: 35
Study 22619101 — intervention group
Group type: COMPARATOR
Intervention: Classic kinesiotherapy (control group)
Number of subjects: 35
Study 20511606 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 24
Study 20511606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17586713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized occlusal form
Number of subjects: 45
Study 17586713 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic occlusal form
Number of subjects: 45
Study 17586713 — intervention group
Group type: COMPARATOR
Intervention: Zero-degree occlusal form
Number of subjects: 45
Study 15087034 — intervention group
Group type: EXPERIMENTAL
Intervention: HMVP regimen (hydroxycamptothecin 12 mg/m² d1-d5, mitomycin C 6 mg/m² d1, vindesine 2.5-3 mg/m² d1 and d8, cisplatin 50 mg/m² d2 and d3)
Number of subjects: 134
Study 15087034 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP regimen (mitomycin C, vindesine, cisplatin same as HMVP)
Number of subjects: 134
Study 15087034 — intervention group
Group type: EXPERIMENTAL
Intervention: HVP regimen (hydroxycamptothecin, vindesine, cisplatin same as HMVP)
Number of subjects: 134
Study 15087034 — intervention group
Group type: COMPARATOR
Intervention: All groups (HMVP, MVP, HVP)
Number of subjects: 134
Study 10644862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 13
Study 10644862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9058157 — intervention group
Group type: COMPARATOR
Intervention: Locoregional targeted chemotherapy only via an arterial catheter (Group A)
Number of subjects: 193
Study 9058157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined locoregional immuno-chemotherapy via two arterial catheters (Group B)
Number of subjects: 193
Study 7839878 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional anti-diabetic medicines (hospital-based trial for about 4 weeks)
Number of subjects: 18
Study 7839878 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional treatment (ambulatory basis for up to 16 weeks)
Number of subjects: 18
Study 2944006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250,000 U) followed by i.v. administration of streptokinase (500,000 U) in group 2.
Number of subjects: 533
Study 2944006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250,000 U) in group 2.
Number of subjects: 533
Study 2944006 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in group 1.
Number of subjects: 533
Study 3351336 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Diproprionate in an optimized vehicle
Number of subjects: 38
Study 3351336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol Proprionate ointment
Number of subjects: 38
Study 3351336 — intervention group
Group type: EXPERIMENTAL
Intervention: GCMS
Number of subjects: 38
Study 3351336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary-free cortisol and 17-hydroxycortisol
Number of subjects: 38
Study 29902649 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS)
Number of subjects: 82
Study 29902649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 28751575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lispro insulin (40 IU)
Number of subjects: 9
Study 28751575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 25935345 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric aspartate kinase BT3
Number of subjects: 0
Study 25935345 — intervention group
Group type: COMPARATOR
Intervention: Typical commercial feedback resistant aspartate kinase AKCfbr
Number of subjects: 0
Study 24069451 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pro-active care by practice nurses (3 monthly review appointments over 2 years)
Number of subjects: 41
Study 24069451 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pro-active care by practice nurses
Number of subjects: 41
Study 24069451 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 41
Study 21518460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg once-daily
Number of subjects: 1647
Study 19446387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 336
Study 19446387 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (1 mg)
Number of subjects: 336
Study 16397814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (750 ml total, 250 ml cranberry juice + 500 ml mineral water)
Number of subjects: 20
Study 16397814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (750 ml total, 750 ml placebo)
Number of subjects: 20
Study 16397814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (750 ml total, 750 ml cranberry juice)
Number of subjects: 20
Study 16397814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (750 ml total, 250 ml placebo + 500 ml mineral water)
Number of subjects: 20
Study 15558391 — intervention group
Group type: EXPERIMENTAL
Intervention: Harrison mirror‐image postural methods (mechanically assisted manipulation, opposite head posture exercise, opposite head translation posture traction)
Number of subjects: 51
Study 15558391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study 11763381 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg)
Number of subjects: 236
Study 11763381 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 236
Study 8991295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 64
Study 8991295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotizability
Number of subjects: 64
Study 8489204 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of zidovudine five times daily
Number of subjects: 40
Study 8489204 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of zidovudine five times daily
Number of subjects: 40
Study 8489204 — intervention group
Group type: COMPARATOR
Intervention: Placebo five times daily
Number of subjects: 40
Study 8489204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rerandomized to zidovudine treatment after week 16
Number of subjects: 40
Study 3812604 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundation Care
Number of subjects: 0
Study 3812604 — intervention group
Group type: COMPARATOR
Intervention: ICF/MR
Number of subjects: 0
Study 29405229 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 13
Study 29405229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26669200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen-stomach needling
Number of subjects: 142
Study 26669200 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (control)
Number of subjects: 142
Study 23104677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE)
Number of subjects: 38
Study 23104677 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 21969650 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making training
Number of subjects: 61
Study 21969650 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 61
Study 19014840 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 371
Study 19014840 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 371
Study 17149460 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyArm (OA)
Number of subjects: 25
Study 17149460 — intervention group
Group type: COMPARATOR
Intervention: Nasal Cannula (NC)
Number of subjects: 25
Study 12633191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 0
Study 12633191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 0
Study 12633191 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0
Study 12633191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fecal occult blood testing and sigmoidoscopy
Number of subjects: 0
Study 10997423 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive oral MR contrast media (Magnevist)
Number of subjects: 50
Study 10997423 — intervention group
Group type: COMPARATOR
Intervention: Negative oral MR contrast media (Abdoscan)
Number of subjects: 50
Study 10997423 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 50
Study 10997423 — intervention group
Group type: COMPARATOR
Intervention: Enteroclysis
Number of subjects: 50
Study 9123628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic scanning of the aorta
Number of subjects: 13500
Study 8233262 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist leuprolide acetate depot for 3 months
Number of subjects: 20
Study 8233262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3545094 — intervention group
Group type: COMPARATOR
Intervention: Educational programme by community child health nurses, visited monthly for six months.
Number of subjects: 368
Study 30672083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 4038
Study 30672083 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 4038
Study 29921076 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transfixion suture
Number of subjects: 40
Study 29921076 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 40
Study 25990559 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 367
Study 25990559 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 367
Study 25990559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 25214290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 79
Study 25214290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (phloroglucinol)
Number of subjects: 79
Study 23234302 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 41
Study 21150279 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 202
Study 21150279 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster
Number of subjects: 202
Study 21150279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 17974538 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush (OT) + Interproximal toothbrush (IT)
Number of subjects: 30
Study 17974538 — intervention group
Group type: COMPARATOR
Intervention: Curved-bristle toothbrush (CBT)
Number of subjects: 30
Study 17974538 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic toothbrush (OT)
Number of subjects: 30
Study 15734344 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (n = 14)
Number of subjects: 28
Study 15734344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study 12269682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 255
Study 12269682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study 9643144 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrostimulation (Amplipul's‐4 unit)
Number of subjects: 29
Study 7989405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen pretreatment (three days)
Number of subjects: 8
Study 7989405 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg single oral dose)
Number of subjects: 8
Study 2686576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (mean dose 150 +/- 53 mg/d)
Number of subjects: 48
Study 2686576 — intervention group
Group type: COMPARATOR
Intervention: Desipramine hydrochloride (mean dose 153 +/- 55 mg/d)
Number of subjects: 48
Study 31987998 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Signal Regression (GSR)
Number of subjects: 38
Study 31987998 — intervention group
Group type: COMPARATOR
Intervention: Model-based physiological nuisance regression
Number of subjects: 38
Study 31356376 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire-assisted cannulation
Number of subjects: 90
Study 31356376 — intervention group
Group type: COMPARATOR
Intervention: Direct cannulation (Control)
Number of subjects: 90
Study 28390501 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based extinction therapy (IbET)
Number of subjects: 140
Study 28390501 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (WL)
Number of subjects: 140
Study 27542131 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy condition
Number of subjects: 185
Study 27542131 — intervention group
Group type: COMPARATOR
Intervention: Education support condition
Number of subjects: 185
Study 24602997 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (activation of a sham electrode) under continuous reinforcement (CRF)
Number of subjects: 60
Study 24602997 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (activation of a sham electrode) under partial reinforcement (PRF)
Number of subjects: 60
Study 24602997 — intervention group
Group type: COMPARATOR
Intervention: Control (no conditioning)
Number of subjects: 60
Study 22682023 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (measured by Oslo-3 Social Support Scale)
Number of subjects: 2387
Study 22682023 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (as a mediator)
Number of subjects: 2387
Study 22682023 — intervention group
Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 2387
Study 20712749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up-titrated to 400 mg/day)
Number of subjects: 155
Study 20712749 — intervention group
Group type: COMPARATOR
Intervention: Lithium (doses adjusted to obtain serum levels of 0.5-1.0 mmol/L)
Number of subjects: 155
Study 20712749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 155
Study 20712749 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 155
Study 17344507 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg elemental Zn/d) for 12 months
Number of subjects: 50
Study 17344507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16389883 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% of maximal 100m freestyle time (95% ITS)
Number of subjects: 8
Study 16389883 — intervention group
Group type: COMPARATOR
Intervention: 0% ITS (control)
Number of subjects: 8
Study 16389883 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ITS
Number of subjects: 8
Study 16389883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 8
Study 12032024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 90 mg
Number of subjects: 80
Study 12032024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9754024 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 106
Study 9754024 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluorometholone
Number of subjects: 106
Study 10203372 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate drink
Number of subjects: 23
Study 10203372 — intervention group
Group type: COMPARATOR
Intervention: Dialysis treatment
Number of subjects: 23
Study 1884880 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (100 mg)
Number of subjects: 16
Study 1884880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6412267 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study 6412267 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31837232 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarettes
Number of subjects: 36
Study 31837232 — intervention group
Group type: COMPARATOR
Intervention: cigarettes
Number of subjects: 36
Study 31837232 — intervention group
Group type: COMPARATOR
Intervention: cig‐a‐like devices
Number of subjects: 36
Study 31837232 — intervention group
Group type: COMPARATOR
Intervention: fixed‐power tank devices
Number of subjects: 36
Study 30638466 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 80
Study 30638466 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional bipolar device)
Number of subjects: 80
Study 28986411 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Leg Illusion (VLI) with synchronous visuotactile stimulation to the lower back
Number of subjects: 40
Study 28986411 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Body Illusion (FBI)
Number of subjects: 40
Study 28986411 — intervention group
Group type: COMPARATOR
Intervention: Virtual Leg Illusion (VLI)
Number of subjects: 40
Study 27294869 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial weight reduction intervention
Number of subjects: 87
Study 27294869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 27832555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 0.2 µg/ml effect-site concentration
Number of subjects: 30
Study 27832555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 0.4 µg/ml effect-site concentration
Number of subjects: 30
Study 27832555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27832555 — intervention group
Group type: COMPARATOR
Intervention: Blood alcohol concentration of 0.05%
Number of subjects: 30
Study 23974276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone therapy (Omnadren 250) for 9 weeks
Number of subjects: 80
Study 23974276 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 80